Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 20/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4430544 | 0.98 | CNR2 (0.73) | CNR2CYP2C9CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL3380295 | 0.93 | CNR2 (0.85) | CNR2CYP2C9CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL3382163 | 0.92 | CNR2 (0.85) | CNR2CYP2C9CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL3378659 | 0.91 | CNR2 (0.85) | CNR2CYP2C9CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL3378107 | 0.90 | CNR2 (0.84) | CNR2CYP2C9CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL3381076 | 0.90 | CNR2 (0.85) | CNR2CYP2C9CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL3379472 | 0.89 | CNR2 (0.84) | CNR2CYP2C9CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL3383131 | 0.89 | CNR2 (0.84) | CNR2CYP2C9CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL3381780 | 0.89 | CNR2 (0.85) | CNR2CYP2C9CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL3380966 | 0.89 | CNR2 (0.85) | CNR2CYP2C9CYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1878725-B1 | Pyrimidine derivatives and their use as CB2 modulators | GLAXO GROUP LTD (GB) | 2010-11-24 | — | — | EP | disclosed |
| US-20100041654-A1 | Pyrimidine Derivatives And Their Use As CB2 Modulators | EATHERTON ANDREW JOHN | 2010-02-18 | — | — | US | disclosed |
| US-20100041654-A1 | Pyrimidine Derivatives And Their Use As CB2 Modulators | EATHERTON ANDREW JOHN | 2010-02-18 | — | — | US | disclosed |
| US-20100041654-A1 | Pyrimidine Derivatives And Their Use As CB2 Modulators | EATHERTON ANDREW JOHN | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041654-A1 | Pyrimidine Derivatives And Their Use As CB2 Modulators | CNR2, CNR1, P2RY2 | CNR2 1/4885CYP2C9 969/4885CYP1A2 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.